Phase 2
Completed N=61
Efavirenz in Treating Patients With Metastatic Prostate Cancer
Source: ClinicalTrials.gov NCT00964002 ↗Enrolled (actual)
61
Serious AEs
18.6%
Results posted
May 2022
Primary outcomePrimary: Percentage of Participants Without Prostate-specific Antigen Progression at 3 Months — 28.3 percentage of participants
Summary
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well efavirenz works in treating patients with metastatic prostate cancer.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants Without Prostate-specific Antigen Progression at 3 Months |
28.3 | — |
| SECONDARY Percentage of Participants Without Prostate-specific Antigen Progression at 6 Months |
11.3 | — |
Eligibility Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed prostate cancer
- Metastatic disease
- Castration-refractory disease
- No clinical symptoms related to disease progression
PATIENT CHARACTERISTICS:
- WHO performance status 0-2
PRIOR CONCURRENT THERAPY:
- Not specified
Data sourced from ClinicalTrials.gov (NCT00964002). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.